Supplier evidence is sufficient for semiconductor wet chemical approval only when it connects the exact chemical grade, manufacturing site, analytical methods, commercial package, and representative lot to process-specific acceptance criteria and change control. A TDS, SDS, generic specification, or sample COA cannot independently approve commercial supply. IPA, H₂O₂, NH₄OH, HCl, HF, H₂SO₄, and defined mixtures require different evidence, but the buyer decision is consistent: approve only what the documents and data actually represent. If that chain is incomplete, hold approval or advance conditionally. The next step is a commercial-lot qualification package request identifying the specific missing evidence.

What Evidence Package Is Actually Being Approved?

A supplier is not technically approved in the abstract. Approval applies to a defined commercial supply configuration:

Chemical Identity → Concentration and Grade → Manufacturing Site → Purification and Final Filtration → Filling Route → Commercial Package → Release Specification and Method

The documents must identify the same configuration. A specification for one grade, a COA from another site, method data from an upstream sample, and a packaging declaration for an undefined container do not form a valid approval package—even if every document appears acceptable separately.

This page addresses the evidence required to approve high-purity liquid chemicals that contact wafers or contamination-sensitive surfaces during cleaning, wet etching, surface conditioning, residue removal, displacement, or drying. It does not cover supplier financial approval, general corporate audits, photoresists, CMP slurries, process gases, deposition precursors, or ultrapure-water system qualification.

ChemicalCell’s semiconductor wet-process chemical qualification framework covers the full relationship among process function, contamination control, testing, packaging, commercial supply, and change control. The narrower decision here is:

Are the supplier’s documents and data sufficient to approve the proposed commercial configuration?

Which Evidence Must Change With the Chemical?

The evidence package cannot be standardized by copying the same purity, water, metal, particle, or packaging requirements onto every wet chemical.

These are evidence categories, not universal specification limits. The actual acceptance criteria must follow:

Process Function → Credible Failure Risk → Critical Parameter → Test Method → Evidence Limitation → Approval Decision

For H₂O₂, for example:

Concentration loss during storage → Changed oxidative condition → Active-concentration and stability data → Release COA cannot prove later condition → Require package- and time-relevant evidence

For HF:

Concentration variation → Changed oxide-removal response → Supplier concentration test plus application evidence where necessary → Analytical conformity cannot independently predict the buyer’s etch result → Require controlled process evaluation before unrestricted approval

For IPA:

Water, residue, metal, or particle contribution → Drying or surface-contamination risk → Relevant analytical results from the delivered package → Small-bottle data may not represent commercial filling → Require a sample-to-commercial-package bridge

What Can Each Document Prove?

The presence of a document does not establish that it supports the commercial approval decision.

A document package remains incomplete when the records cannot be traced to the same:

• Product code and grade;
• Manufacturing and filling site;
• Specification revision;
• Analytical method revision;
• Batch and sampling point;
• Commercial package configuration.

A COA stating only “Pass” may confirm that the supplier applied its own release decision. It does not allow the buyer to examine actual values, reporting limits, proximity to acceptance limits, or batch-to-batch movement.

Likewise, a lower impurity value from Supplier B does not establish better material when Supplier A and Supplier B use different units, preparation methods, reporting limits, particle channels, or sampling locations.

When Are Supplier Results Directly Comparable?

Two results should be compared only when the following conditions are aligned:

1. The chemical, concentration, grade, manufacturing site, and specification scope are equivalent.
2. The analyte or parameter is defined in the same way.
3. The unit and calculation basis are compatible.
4. The sample preparation, analytical method, reporting limit, and decision rule can support the same acceptance limit.
5. The sampling point and package state represent the same stage of supply.
6. The test timing reflects comparable filling, storage, and contact conditions.

“ND” is not a concentration and does not mean zero. Its qualification value depends on the associated method detection or reporting limit. SEMI C10 states that method detection capability for relevant trace contaminants should be equal to or below the applicable specification.

For trace-metal comparison, the buyer should also examine matrix effects, blanks, sample preparation, filtration status, unit basis, and container contribution. ChemicalCell’s guide to ICP-MS trace-metal data for electronic-grade solvents addresses these limitations in greater detail.

When supplier and buyer results cannot be reconciled, approval should remain on hold until method comparability is established. A controlled split-sample study may be appropriate when both laboratories use aligned containers, sample handling, analyte lists, units, reporting limits, and data-processing rules.

When Does Packaging Evidence Become Approval-Critical?

Packaging evidence becomes approval-critical when the proposed container or filling system can change a parameter that matters to the application.

The review should include the complete wetted path:

Filling Equipment → Transfer Connection → Container → Closure and Liner → Seal or Gasket → Valve or Dip Tube → Sampling and Dispensing

Possible contributions include particles, metallic or ionic contamination, extracted organics, nonvolatile residue, water ingress, volatile loss, concentration change, or chemical degradation. Not every pathway is relevant to every chemical.

A polymer name alone is not sufficient. Two packages described as HDPE can differ in resin formulation, manufacturing history, cleaning, closure components, filling route, and contact geometry. Likewise, a PFA component does not prove that the complete assembled package is suitable.

SEMI F57 addresses high-purity polymer materials and components, including metallic, ionic, organic, traceability, and packaging considerations. Its primary test basis and stated boundaries also show why buyers may need chemistry- and condition-specific testing rather than transferring one polymer result to every wet chemical.

Packaging evidence should therefore identify:

• The exact commercial container and all approval-relevant wetted components;
• Cleaning and pretreatment conditions;
• Chemical, temperature, and contact duration used in compatibility testing;
• Sampling location relative to final filtration and filling;
• Whether analytical results were obtained before or after commercial packaging.

Applied Decision Example: An IPA Sample Passes, but the Commercial Package Changes

Assume a supplier submits an IPA specification and a passing COA from a small evaluation bottle. The proposed commercial supply will use a different filling line and bulk package.

The submitted evidence may establish:

• IPA identity and nominal assay;
• Initial application compatibility;
• Selected impurity results for the evaluation sample;
• Compliance of that sample with the supplier’s release specification.

It does not independently establish:

• Water control after routine bulk filling and storage;
• Particle contribution from the commercial container, valve, or dispensing path;
• Elemental contamination introduced after final filtration;
• NVR or extractables after contact with the intended package;
• Equivalence between the sample-filling and commercial-filling routes.

SEMI C41 can provide a specification and testing reference for semiconductor-industry 2-propanol. It does not prove that a particular commercial package preserves the buyer’s process-specific limits.

The correct decision is therefore conditional advancement, not unrestricted commercial approval.

The supplier should be asked for:

• The exact sample and commercial-package configurations;
• Differences in filling route and wetted components;
• Comparable water, particle, selected metal, and NVR data where these risks are approval-critical;
• Results from representative final-packaged commercial material;
• The commercial-lot COA and applicable method information.

If the commercial-package results meet the agreed limits using decision-capable methods, the defined configuration may be approved. If the filling route or wetted components remain unidentified, approval should remain on hold.

ChemicalCell’s guide to sample-to-commercial-package qualification for electronic-grade solvents provides the detailed packaging-equivalence review for this situation.

Approve, Conditionally Advance, or Hold?

Missing evidence does not always justify rejecting the supplier. It justifies withholding unrestricted approval until the defined gap is closed.

The proposed configuration should not be approved when it fails agreed acceptance criteria, cannot be connected to representative commercial supply, or remains dependent on methods that cannot evaluate compliance.

Which Changes Require Requalification?

A change requires review when it makes part of the original approval evidence uncertain. The response should follow the affected risk rather than automatically repeat the entire qualification program.

• Analytical method, preparation, instrument, or reporting-limit change: establish method comparability and continuity with historical data.
• Container, closure, valve, filling-line, or cleaning change: repeat only the packaging-sensitive tests affected by the new wetted path.
• Raw-material source, purification process, final filter, or manufacturing-site change: reassess the broader impurity profile, method evidence, representative lot, and process performance where relevant.
• Concentration, stabilizer, or mixture-ratio change: reassess both functional performance and contamination requirements.
• Storage condition or shelf-life change: confirm stability for the revised chemical-and-package combination.

The approval record or quality agreement should define which changes require notification, what evidence must accompany the notification, and whether supply can continue while the change is reviewed.

Request the Commercial-Lot Qualification Package

The next step should be a commercial-lot qualification package request—not a general request for “more documents.”

For a second source, provide the required acceptance basis rather than asking the candidate supplier to reproduce the incumbent’s manufacturing process. The comparison should establish equivalent qualification evidence, not identical production routes or visually similar COAs.

When submitting a ChemicalCell chemical RFQ, identify the exact material and application, attach the applicable purchasing specification where available, and state which commercial-lot, packaging, method, or change-control evidence is required. The availability of a particular grade, package, sample, test report, or supporting document should be confirmed for the specific inquiry.

The supplier can be approved only when the specification, method, lot result, commercial package, and change-control record describe the same material that will enter routine supply.